Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion?

被引:13
作者
Ma, Ka Wing [1 ]
Chan, Albert Chi Yan [1 ]
Chok, Kenneth Siu Ho [1 ]
She, Wong Hoi [1 ]
Cheung, Tan To [1 ]
Dai, Wing Chiu [1 ]
Fung, James Yan Yue [2 ]
Lo, Chung Mau [1 ]
机构
[1] Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
关键词
Liver transplantation (LT); portal vein; tumour thrombus; liver resection (LR); LIVING DONOR; HEPATIC RESECTION; SORAFENIB; SURVIVAL; OUTCOMES; CHEMOEMBOLIZATION; EFFICACY; SAFETY;
D O I
10.21037/hbsn.2020.03.09
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT) signifies advanced disease, whether LT confers any survival superiority over resection remains uncertain. Methods: A propensity score matched (PSM) analysis of liver transplantation (LT) and liver resection (LR) for HCC with PVTT was performed. Results: A consecutive series of 88 patients who received either LT (10 DDLTs and 3 LDLTs) or LR (n=75) respectively were recruited. Before PSM, the LT group has a higher MELD score (17.3 vs. 7.8, P<0.001), lower serum AFP levels (96 vs. 2,164 ng/mL, P=0.017) and smaller tumour size (4 vs. 10 cm, P<0.001). The 5-year overall survival for LT and LR were 55.4% and 15.9% respectively (P=0.007). After matching for serum AFP levels and tumour size, 1-, 3-and 5-year overall survival for LT were 81 ng/mL, 3.9 cm, 80%, 70% and 70% and the corresponding rates for LR were 1,417 ng/mL, 5.3 cm, 51.8%, 19,6% and 9.8% (P value =0.12, 0.27 and 0.009 respectively). Conclusions: LT is associated with significantly better oncological outcomes in HCC patients with PVTT involving the lobar or segmental level. A modest expansion of selection criteria to include small HCC with segmental PVTT should be considered.
引用
收藏
页码:308 / 314
页数:7
相关论文
共 34 条
[1]   Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial [J].
Bruix, Jordi ;
Raoul, Jean-Luc ;
Sherman, Morris ;
Mazzaferro, Vincenzo ;
Bolondi, Luigi ;
Craxi, Antonio ;
Galle, Peter R. ;
Santoro, Armando ;
Beaugrand, Michel ;
Sangiovanni, Angelo ;
Porta, Camillo ;
Gerken, Guido ;
Marrero, Jorge A. ;
Nadel, Andrea ;
Shan, Michael ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Llovet, Josep M. .
JOURNAL OF HEPATOLOGY, 2012, 57 (04) :821-829
[2]   Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: Extending the Indication for resection? [J].
Chang, Wen-Tsan ;
Kao, Wei-Yu ;
Chau, Gar-Yang ;
Su, Chien-Wei ;
Lei, Hao-Jan ;
Wu, Jaw-Ching ;
Hsia, Cheng-Yuan ;
Lui, Wing-Yiu ;
King, Kuang-Liang ;
Lee, Shou-Dong .
SURGERY, 2012, 152 (05) :809-820
[3]   Why does living donor liver transplantation flourish in Asia? [J].
Chen, Chao-Long ;
Kabiling, Catherine S. ;
Concejero, Allan M. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (12) :746-751
[4]   Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial [J].
Cheng, Ann-Lii ;
Guan, Zhongzhen ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Yang, Tsai-Sheng ;
Tak, Won Young ;
Pan, Hongming ;
Yu, Shiying ;
Xu, Jianming ;
Fang, Fang ;
Zou, Jessie ;
Lentini, Giuseppe ;
Voliotis, Dimitris ;
Kang, Yoon-Koo .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) :1452-1465
[5]   The Clinical Outcomes of Patients with Portal Vein Tumor Thrombi After Living Donor Liver Transplantation [J].
Choi, Ho Joong ;
Kim, Dong Goo ;
Na, Gun Hyung ;
Hong, Tae Ho ;
Bae, Si Hyun ;
You, Young Kyoung ;
Choi, Jong Young ;
Yoon, Seung Kew .
LIVER TRANSPLANTATION, 2017, 23 (08) :1023-1031
[6]   Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis [J].
Chok, Kenneth S. H. ;
Cheung, Tan To ;
Chan, See Ching ;
Poon, Ronnie T. P. ;
Fan, Sheung Tat ;
Lo, Chung Mau .
WORLD JOURNAL OF SURGERY, 2014, 38 (02) :490-496
[7]   Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma [J].
Cillo, U ;
Vitale, A ;
Bassanello, M ;
Boccagni, P ;
Brolese, A ;
Zanus, G ;
Burra, P ;
Fagiuoli, S ;
Farinati, F ;
Rugge, M ;
D'Amico, DF .
ANNALS OF SURGERY, 2004, 239 (02) :150-159
[8]   Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan [J].
Concejero, Allan ;
Chen, Chao-Long ;
Wang, Chih-Chi ;
Wang, Shih-Ho ;
Lin, Chih-Che ;
Liu, Yueh-Wei ;
Yang, Chin-Hsiang ;
Yong, Chee-Chien ;
Lin, Tsan-Shiun ;
Jawan, Bruno ;
Huang, Tung-Liang ;
Cheng, Yu-Fan ;
Eng, Hock-Liew .
TRANSPLANTATION, 2008, 85 (03) :398-406
[9]   CURRENT CONCEPTS Hepatocellular Carcinoma [J].
El-Serag, Hashem B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) :1118-1127
[10]   Hepatocellular carcinoma - An epidemiologic view [J].
El-Serag, HB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 35 (05) :S72-S78